WO2013013143A1 - Fixed dose combination of bimatoprost and brimonidine - Google Patents
Fixed dose combination of bimatoprost and brimonidine Download PDFInfo
- Publication number
- WO2013013143A1 WO2013013143A1 PCT/US2012/047586 US2012047586W WO2013013143A1 WO 2013013143 A1 WO2013013143 A1 WO 2013013143A1 US 2012047586 W US2012047586 W US 2012047586W WO 2013013143 A1 WO2013013143 A1 WO 2013013143A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- brimonidine
- bimatoprost
- glaucoma
- intraocular pressure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12741222.9A EP2734206A1 (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
CA2841969A CA2841969A1 (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
BR112014001118A BR112014001118A2 (en) | 2011-07-20 | 2012-07-20 | topical combination for ophthalmic application and use of bimatoprost and brimonidine |
MX2014000781A MX2014000781A (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine. |
RU2014103544/15A RU2014103544A (en) | 2011-07-20 | 2012-07-20 | COMBINATION OF FIXED DOSES OF BIMATOPROST AND BRIMONIDINE |
AU2012283895A AU2012283895A1 (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
JP2014521822A JP2014520895A (en) | 2011-07-20 | 2012-07-20 | Combination of fixed doses of bimatoprost and brimonidine |
US14/235,746 US20140249153A1 (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
KR1020147004214A KR20140056280A (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
CN201280041251.3A CN103747786A (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
IL230450A IL230450A0 (en) | 2011-07-20 | 2014-01-14 | Fixed dose combination of bimatoprost and brimonidine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509666P | 2011-07-20 | 2011-07-20 | |
US61/509,666 | 2011-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013013143A1 true WO2013013143A1 (en) | 2013-01-24 |
Family
ID=46599013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/047586 WO2013013143A1 (en) | 2011-07-20 | 2012-07-20 | Fixed dose combination of bimatoprost and brimonidine |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130023536A1 (en) |
EP (1) | EP2734206A1 (en) |
JP (2) | JP2014520895A (en) |
KR (1) | KR20140056280A (en) |
CN (1) | CN103747786A (en) |
AU (1) | AU2012283895A1 (en) |
BR (1) | BR112014001118A2 (en) |
CA (1) | CA2841969A1 (en) |
CO (1) | CO6880070A2 (en) |
IL (1) | IL230450A0 (en) |
MX (1) | MX2014000781A (en) |
RU (1) | RU2014103544A (en) |
WO (1) | WO2013013143A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013090842A3 (en) * | 2011-12-16 | 2013-10-10 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymers (soluplus) |
WO2013163219A1 (en) * | 2012-04-24 | 2013-10-31 | Allergan, Inc. | Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
WO2019236148A1 (en) * | 2017-06-08 | 2019-12-12 | Eye Therapies, Llc | Low-dose brimonidine combinations and uses thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2753788T3 (en) * | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
UA118576C2 (en) * | 2014-01-24 | 2019-02-11 | Сентис Фарма Прайвет Лімітед | Pharmaceutical composition comprising brinzolamide |
WO2016063184A1 (en) * | 2014-10-20 | 2016-04-28 | Sentiss Pharma Private Limited | Ophthalmic solution |
TWI699205B (en) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | Drug therapy used to prevent or treat glaucoma |
CN107405303A (en) * | 2015-03-24 | 2017-11-28 | 陶氏环球技术有限责任公司 | The aqueous solution of polymer |
PL3103439T3 (en) * | 2015-06-09 | 2019-12-31 | Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh | Drippable ophthalmic bimatoprost gel |
KR102115285B1 (en) | 2017-06-22 | 2020-05-26 | 연성정밀화학(주) | Eye Drop Composition for Treating Glaucoma |
JP7170436B2 (en) * | 2017-06-28 | 2022-11-14 | 千寿製薬株式会社 | Ophthalmic solution containing water-soluble polymer |
WO2020219707A1 (en) * | 2019-04-24 | 2020-10-29 | Allergan, Inc. | Compositions and methods for treatment of ocular conditions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013267A2 (en) * | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2001A (en) * | 1841-03-12 | Sawmill |
-
2012
- 2012-07-20 BR BR112014001118A patent/BR112014001118A2/en not_active IP Right Cessation
- 2012-07-20 RU RU2014103544/15A patent/RU2014103544A/en unknown
- 2012-07-20 AU AU2012283895A patent/AU2012283895A1/en not_active Abandoned
- 2012-07-20 MX MX2014000781A patent/MX2014000781A/en not_active Application Discontinuation
- 2012-07-20 KR KR1020147004214A patent/KR20140056280A/en not_active Application Discontinuation
- 2012-07-20 US US13/554,372 patent/US20130023536A1/en not_active Abandoned
- 2012-07-20 CA CA2841969A patent/CA2841969A1/en not_active Abandoned
- 2012-07-20 EP EP12741222.9A patent/EP2734206A1/en not_active Withdrawn
- 2012-07-20 JP JP2014521822A patent/JP2014520895A/en active Pending
- 2012-07-20 WO PCT/US2012/047586 patent/WO2013013143A1/en active Application Filing
- 2012-07-20 US US14/235,746 patent/US20140249153A1/en not_active Abandoned
- 2012-07-20 CN CN201280041251.3A patent/CN103747786A/en active Pending
-
2014
- 2014-01-14 IL IL230450A patent/IL230450A0/en unknown
- 2014-02-18 CO CO14033887A patent/CO6880070A2/en unknown
-
2015
- 2015-03-18 JP JP2015054576A patent/JP2015110672A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013267A2 (en) * | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
Non-Patent Citations (4)
Title |
---|
BASF: "Soluplus -Technical information", INTERNET CITATION, July 2010 (2010-07-01), pages 1 - 8, XP002666808, Retrieved from the Internet <URL:http://www.pharma-ingredients.basf.com/Statements/Technical%20Informations/EN/Pharma%20Solutions/03_090801e_Soluplus.pdf> [retrieved on 20120110] * |
BOURNIAS T E ET AL: "Brimonidine Tartrate 0.15%, Dorzolamide Hydrochloride 2%, and Brinzolamide 1% Compared as Adjunctive Therapy to Prostaglandin Analogs", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 116, no. 9, 1 September 2009 (2009-09-01), pages 1719 - 1724, XP026546517, ISSN: 0161-6420, [retrieved on 20090709], DOI: 10.1016/J.OPHTHA.2009.03.050 * |
NETLAND PETER A ET AL: "Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 20, no. 1, 1 January 2003 (2003-01-01), pages 20 - 30, XP009146371, ISSN: 0741-238X, DOI: 10.1007/BF02850116 * |
NIXON DONALD R ET AL: "Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination", CURRENT MEDICAL RESEARCH AND OPINION,, vol. 25, no. 7, 1 July 2009 (2009-07-01), pages 1645 - 1653, XP009146366, ISSN: 1473-4877, [retrieved on 20090528], DOI: 10.1185/03007990902994041 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013090842A3 (en) * | 2011-12-16 | 2013-10-10 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymers (soluplus) |
US9579385B2 (en) | 2011-12-16 | 2017-02-28 | Allergan, Inc. | Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers |
WO2013163219A1 (en) * | 2012-04-24 | 2013-10-31 | Allergan, Inc. | Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
US9248135B2 (en) | 2012-04-24 | 2016-02-02 | Allergan, Inc. | Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
US9579328B2 (en) | 2012-04-24 | 2017-02-28 | Allergan, Inc. | Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use |
WO2019236148A1 (en) * | 2017-06-08 | 2019-12-12 | Eye Therapies, Llc | Low-dose brimonidine combinations and uses thereof |
AU2018279074B2 (en) * | 2017-06-08 | 2023-12-14 | Eye Therapies, Llc | Low-dose brimonidine combinations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2015110672A (en) | 2015-06-18 |
JP2014520895A (en) | 2014-08-25 |
CO6880070A2 (en) | 2014-02-28 |
IL230450A0 (en) | 2014-03-31 |
KR20140056280A (en) | 2014-05-09 |
EP2734206A1 (en) | 2014-05-28 |
BR112014001118A2 (en) | 2017-02-14 |
AU2012283895A1 (en) | 2014-02-06 |
CN103747786A (en) | 2014-04-23 |
MX2014000781A (en) | 2014-04-30 |
RU2014103544A (en) | 2015-08-27 |
US20140249153A1 (en) | 2014-09-04 |
CA2841969A1 (en) | 2013-01-24 |
US20130023536A1 (en) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2734206A1 (en) | Fixed dose combination of bimatoprost and brimonidine | |
CA2502437C (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
US8680078B2 (en) | Stable ophthalmic formulations | |
US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
US6740660B2 (en) | Nasal delivery of apomorphine | |
JP5244584B2 (en) | Ophthalmic composition containing xanthan gum and glucose | |
US20120322871A1 (en) | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | |
BRPI0714587A2 (en) | aqueous ophthalmic sulfur and use of nesna | |
KR20140009332A (en) | High concentration olopatadine ophthalmic composition | |
JP6436354B2 (en) | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual function | |
CN106455567A (en) | Compositions and methods for treatment of glaucoma | |
KR20130100273A (en) | Aqueous composition for ophthalmic administration | |
CN112972683A (en) | Locally administered medicinal composition of gellinzomib and the like | |
JP2020514347A (en) | Myopia prevention, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient | |
JP2003128553A (en) | Ophthalmic composition | |
US11273141B2 (en) | Low-dose carbachol compositions and methods for treatment of night vision disturbance | |
JP6963651B2 (en) | Aqueous composition containing epinastine or a salt thereof | |
JPH078788B2 (en) | Ophthalmic pharmaceutical composition having mydriatic action | |
JP7118579B1 (en) | Aqueous composition containing epinastine or its salt | |
US20070093507A1 (en) | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | |
JP2024515714A (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions - Patents.com |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741222 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2841969 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014521822 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/000781 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2012283895 Country of ref document: AU Date of ref document: 20120720 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012741222 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14033887 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 20147004214 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014103544 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14235746 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014001118 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014001118 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140116 |